US/UK/Canada

Share

Contacts

  • Marika Nestor

    CEO


    +46702341881
    https://akiramtherapeutics.se/

    • Links

    Quotes

    With this agreement and the GMP production of the affinity carrier in place, we have everything needed to apply for a first-in-human clinical study in 2024. We are very excited and strongly motivated to progress this important project in close collaboration with our clinical colleagues at Karolinska University Hospital.
    Marika Nestor, CEO, Akiram Therapeutics
    It is with great pleasure that we welcome Anna Törner and Peder Walberg to Akiram's board. We are facing important developmental steps, and their investment and commitment to the company are strong indications of confidence in our strategic direction and our ability to realize our goals in cancer treatment.
    Marika Nestor, CEO, Akiram Therapeutics
    The grant is a testament to our commitment to pioneering cancer treatments. This generous support from the Erling-Persson Foundation allows us to advance our mission, offering hope and potential solutions to individuals suffering from incurable cancers.
    Marika Nestor, CEO, Akiram Therapeutics
    We are honored to have the opportunity to present at the Annual EANM Congress. We look forward to sharing promising data about our drug candidate, which we believe holds the potential to significantly impact patient care and radiopharmaceutical sciences in the future. Participating in this global conversation that's shaping the future of Nuclear Medicine is genuinely exciting.
    Dr. Anja Mortenson, co-founder and CTO, Akiram Therapeutics
    We would like to thank Sciety and all those who have participated in this successful issue for the great confidence in Akiram and our drug candidate. We now have the means to continue our work at full speed and take the next important steps on our exciting journey. We are very eager to continue the development of our drug candidate and to initiate phase I clinical studies.
    Marika Nestor, CEO, Akiram Therapeutics
    Pick a time period -
    Tags ( Active)

    Akiram Therapeutics announces agreement with leading university hospital on AKIR001 manufacturing for cancer therapy

    Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, has entered into an agreement with a leading Swedish university hospital for the manufacturing of [177]Lu-AKIR001, a radiopharmaceutical designed for treating patients with solid tumors. This agreement marks an important step towards the Phase I first-in-human study, which is planned to start in 2024.Akiram Therapeutics has developed a new type of targeted radioimmunotherapy, [177]Lu-AKIR001. The therapy holds the potential to become a first-in-class treatment in multiple cancer types, including anaplastic

    Akiram Therapeutics strengthens board with drug development expertise

    Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, is pleased to announce the addition of Anna Törner and Peder Walberg to its board of directors. Their combined expertise in drug development and regulatory affairs fortifies the company's position as it advances toward the planned clinical trials of an innovative cancer treatment in 2024. Additionally, both Törner and Walberg will be investing in the company.Akiram Therapeutics has developed [177]Lu-AKIR001, a novel targeted radioimmunotherapy with the potential to become a first-in-class treatment in

    Akiram Therapeutics’ pioneering cancer research backed by SEK 6 million from the Erling-Persson Foundation

    Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, is pleased to announce that the company’s founder, Professor Marika Nestor and her research group at Uppsala University have been granted SEK 6 million by the Erling-Persson Foundation. This funding will advance a groundbreaking research project aimed at developing novel radiopharmaceuticals for the treatment of aggressive cancers and bolster Akiram’s upcoming Phase I first-in-human human study scheduled for 2024.Akiram Therapeutics has developed a novel targeted radioimmunotherapy called [177]Lu-AKIR001.

    Akiram Therapeutics to present promising data on the therapeutic potential of its drug candidate at EANM Congress

    Akiram Therapeutics, a Swedish biotech company specializing in radiotherapy will present promising preclinical data at the European Association of Nuclear Medicine (EANM) Congress taking place in Vienna, Austria on September 9–13. The data showcases the potential of the company’s radiopharmaceutical [177]Lu-AKIR001 targeting tumor lesions for therapeutic purposes. A Phase 1 study is planned for 2024.Akiram Therapeutics has developed a new type of targeted radioimmunotherapy, [177]Lu-AKIR001. The therapy has shown promising results in several preclinical studies and holds the potential to

    Akiram Therapeutics raises SEK 68 million for clinical development of a drug candidate for rare thyroid cancers

    The Swedish radioimmunotherapy company Akiram Therapeutics, developing targeted cancer therapy, has raised SEK 68 million in a share issue led by Sciety and the network Sciety Venture Partners. The investment company Linc AB participated in the share issue with SEK 20 million. The proceeds from the financing will be used for GMP production of the drug candidate and for initiating a phase I clinical study.Akiram Therapeutics has developed a new type of targeted radioimmunotherapy for anaplastic thyroid cancer. There is no effective treatment for this disease today, and patients survive only

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media